171 related articles for article (PubMed ID: 27022067)
1. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers.
Chi KN; Yu EY; Jacobs C; Bazov J; Kollmannsberger C; Higano CS; Mukherjee SD; Gleave ME; Stewart PS; Hotte SJ
Ann Oncol; 2016 Jun; 27(6):1116-1122. PubMed ID: 27022067
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.
Yu EY; Ellard SL; Hotte SJ; Gingerich JR; Joshua AM; Gleave ME; Chi KN
Invest New Drugs; 2018 Apr; 36(2):278-287. PubMed ID: 29250742
[TBL] [Abstract][Full Text] [Related]
3. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
4. Heat shock protein 27 knockdown using nucleotide‑based therapies enhances sensitivity to 5-FU chemotherapy in SW480 human colon cancer cells.
Shimada T; Tsuruta M; Hasegawa H; Okabayashi K; Shigeta K; Ishida T; Asada Y; Suzumura H; Koishikawa K; Akimoto S; Kitagawa Y
Oncol Rep; 2018 Mar; 39(3):1119-1124. PubMed ID: 29328475
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.
Ko AH; Murphy PB; Peyton JD; Shipley DL; Al-Hazzouri A; Rodriguez FA; Womack MS; Xiong HQ; Waterhouse DM; Tempero MA; Guo S; Lane CM; Earwood C; DeBusk LM; Bendell JC
Oncologist; 2017 Dec; 22(12):1427-e129. PubMed ID: 28935773
[TBL] [Abstract][Full Text] [Related]
6. Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.
Bellmunt J; Eigl BJ; Senkus E; Loriot Y; Twardowski P; Castellano D; Blais N; Sridhar SS; Sternberg CN; Retz M; Pal S; Blumenstein B; Jacobs C; Stewart PS; Petrylak DP
Ann Oncol; 2017 Oct; 28(10):2481-2488. PubMed ID: 28961845
[TBL] [Abstract][Full Text] [Related]
7. DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.
Le TK; Cherif C; Omabe K; Paris C; Lannes F; Audebert S; Baudelet E; Hamimed M; Barbolosi D; Finetti P; Bastide C; Fazli L; Gleave M; Bertucci F; Taïeb D; Rocchi P
Mol Ther; 2023 Feb; 31(2):471-486. PubMed ID: 35965411
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.
Spigel DR; Shipley DL; Waterhouse DM; Jones SF; Ward PJ; Shih KC; Hemphill B; McCleod M; Whorf RC; Page RD; Stilwill J; Mekhail T; Jacobs C; Burris HA; Hainsworth JD
Oncologist; 2019 Dec; 24(12):e1409-e1416. PubMed ID: 31420467
[TBL] [Abstract][Full Text] [Related]
9. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
Chi KN; Eisenhauer E; Fazli L; Jones EC; Goldenberg SL; Powers J; Tu D; Gleave ME
J Natl Cancer Inst; 2005 Sep; 97(17):1287-96. PubMed ID: 16145049
[TBL] [Abstract][Full Text] [Related]
10. The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets.
Katsogiannou M; Andrieu C; Baylot V; Baudot A; Dusetti NJ; Gayet O; Finetti P; Garrido C; Birnbaum D; Bertucci F; Brun C; Rocchi P
Mol Cell Proteomics; 2014 Dec; 13(12):3585-601. PubMed ID: 25277244
[TBL] [Abstract][Full Text] [Related]
11. Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).
Rosenberg JE; Hahn NM; Regan MM; Werner L; Alva A; George S; Picus J; Alter R; Balar A; Hoffman-Censits J; Grivas P; Lauer R; Guancial EA; Hoimes C; Sonpavde G; Albany C; Stein MN; Breen T; Jacobs C; Anderson K; Bellmunt J; Lalani AA; Pal S; Choueiri TK
Br J Cancer; 2018 May; 118(11):1434-1441. PubMed ID: 29765151
[TBL] [Abstract][Full Text] [Related]
12. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
Barata PC; Cooney M; Mendiratta P; Gupta R; Dreicer R; Garcia JA
Invest New Drugs; 2019 Apr; 37(2):331-337. PubMed ID: 30402678
[TBL] [Abstract][Full Text] [Related]
14. OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer.
Baylot V; Andrieu C; Katsogiannou M; Taieb D; Garcia S; Giusiano S; Acunzo J; Iovanna J; Gleave M; Garrido C; Rocchi P
Cell Death Dis; 2011 Oct; 2(10):e221. PubMed ID: 22012255
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Autio KA; Dreicer R; Anderson J; Garcia JA; Alva A; Hart LL; Milowsky MI; Posadas EM; Ryan CJ; Graf RP; Dittamore R; Schreiber NA; Summa JM; Youssoufian H; Morris MJ; Scher HI
JAMA Oncol; 2018 Oct; 4(10):1344-1351. PubMed ID: 29978216
[TBL] [Abstract][Full Text] [Related]
16. Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of
Tagawa ST; Thomas C; Sartor AO; Sun M; Stangl-Kremser J; Bissassar M; Vallabhajosula S; Huicochea Castellanos S; Nauseef JT; Sternberg CN; Molina A; Ballman K; Nanus DM; Osborne JR; Bander NH
J Clin Oncol; 2024 Mar; 42(7):842-851. PubMed ID: 37922438
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
Chi KN; Siu LL; Hirte H; Hotte SJ; Knox J; Kollmansberger C; Gleave M; Guns E; Powers J; Walsh W; Tu D; Eisenhauer E
Clin Cancer Res; 2008 Feb; 14(3):833-9. PubMed ID: 18245546
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
[TBL] [Abstract][Full Text] [Related]
19. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer.
Shiota M; Bishop JL; Nip KM; Zardan A; Takeuchi A; Cordonnier T; Beraldi E; Bazov J; Fazli L; Chi K; Gleave M; Zoubeidi A
Cancer Res; 2013 May; 73(10):3109-19. PubMed ID: 23492367
[TBL] [Abstract][Full Text] [Related]
20. Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer.
Matsui Y; Hadaschik BA; Fazli L; Andersen RJ; Gleave ME; So AI
Mol Cancer Ther; 2009 Aug; 8(8):2402-11. PubMed ID: 19625496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
